N-acetylcysteine, a novel treatment for Helicobacter pylori infection

Area of Science:

• Microbiology
• Gastroenterology
• Pharmacology

Background:

• Helicobacter pylori (H. pylori) infection is a major cause of gastritis and peptic ulcers.
• N-Acetylcysteine (NAC) possesses mucolytic and antioxidant properties, suggesting potential roles in modulating H. pylori infection.
• The impact of NAC on H. pylori colonization and associated gastric pathology requires investigation.

Purpose of the Study:

• To evaluate the in vitro and in vivo effects of N-Acetylcysteine (NAC) on Helicobacter pylori (H. pylori) growth and infection.
• To assess NAC's influence on H. pylori load, gastric mucosal hydrophobicity, and gastritis severity in a murine model.

Main Methods:

• Minimum Inhibitory Concentration (MIC) of NAC against H. pylori was determined using agar and broth dilution methods.
• H. pylori load was quantified in infected mice treated with NAC or sham.
• Gastric mucosal hydrophobicity and gastritis scores were assessed.

Main Results:

• NAC exhibited inhibitory activity against H. pylori, with MICs ranging from 5-15 mg/ml depending on the method.
• NAC administration (120 mg/day for 14 days) significantly reduced H. pylori load in mice by approximately 1 log.
• Both H. pylori infection and NAC treatment decreased gastric surface hydrophobicity; NAC did not alter gastritis scores.

Conclusions:

• N-Acetylcysteine demonstrates direct inhibitory effects on H. pylori growth in vitro and reduces bacterial burden in vivo.
• NAC may influence the gastric environment by altering mucosal hydrophobicity.
• NAC does not exacerbate H. pylori- or H. felis-induced gastritis in this model.